Treats hypertension. ANDA 76333, held by Ani Pharms. Benazepril Hydrochloride.
As of Nov 16, 2026, ANDA 76333 (Benazepril Hydrochloride), held by Ani Pharms, was first approved by FDA on Feb 11, 2004, with 2 approved supplements and 0 published complete response letters.
1. INDICATIONS AND USAGE Benazepril Hydrochloride Tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 11, 2004 | Original application | Approved |
| Benazepril Hydrochloride5MG · tablet;oral | Benazepril Hydrochloride | Rx |
| Benazepril Hydrochloride10MG · tablet;oral | Benazepril Hydrochloride | Rx |
| Benazepril Hydrochloride20MG · tablet;oral | Benazepril Hydrochloride | Rx |
| Benazepril Hydrochloride40MG · tablet;oral | Benazepril Hydrochloride | Rx |
| Nov 28, 2017 | Supplement 11Labeling · Standard review | Approved | None posted |
| May 18, 2005 | Supplement 6Labeling | Approved | None posted |
| Feb 11, 2004 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters